Dr James McNamara
Dr James McNamara
Dr. James McNamara is a National Heart Foundation Future Leader Fellow and Team Leader of Muscle Signalling at Murdoch Children’s Research Institute (MCRI). His research has focused on molecular mechanisms of inherited cardiomyopathies in which he has made several seminal discoveries. He received his PhD in 2017 from the University of Sydney and subsequently undertook postdoctoral training at the University of Cincinnati, supported by the prestigious American Heart Association postdoctoral fellowship.
In 2020 he joined Professor Enzo Porrello and Associate Professor David Elliott’s groups at MCRI. Here, has risen to Team Leader, where he continues to study molecular mechanisms of genetic heart diseases, utilising both human pluripotent stem cells as a human model of disease. At seven years post PhD, his research has attracted over $3 million in competitive funding and has been featured in leading journals such as Nature Cardiovascular Research, Science Translational Medicine, and Cell Metabolism. Recently, he has focused on the molecular function of the atypical kinase, ALPK3, in cardiac health and disease, which forms the basis of this award.
In 2020 he joined Professor Enzo Porrello and Associate Professor David Elliott’s groups at MCRI. Here, has risen to Team Leader, where he continues to study molecular mechanisms of genetic heart diseases, utilising both human pluripotent stem cells as a human model of disease. At seven years post PhD, his research has attracted over $3 million in competitive funding and has been featured in leading journals such as Nature Cardiovascular Research, Science Translational Medicine, and Cell Metabolism. Recently, he has focused on the molecular function of the atypical kinase, ALPK3, in cardiac health and disease, which forms the basis of this award.
Dr. James McNamara is a National Heart Foundation Future Leader Fellow and Team Leader of Muscle Signalling at Murdoch Children’s Research Institute (MCRI). His research has focused on molecular mechanisms of inherited cardiomyopathies in which he...
Dr. James McNamara is a National Heart Foundation Future Leader Fellow and Team Leader of Muscle Signalling at Murdoch Children’s Research Institute (MCRI). His research has focused on molecular mechanisms of inherited cardiomyopathies in which he has made several seminal discoveries. He received his PhD in 2017 from the University of Sydney and subsequently undertook postdoctoral training at the University of Cincinnati, supported by the prestigious American Heart Association postdoctoral fellowship.
In 2020 he joined Professor Enzo Porrello and Associate Professor David Elliott’s groups at MCRI. Here, has risen to Team Leader, where he continues to study molecular mechanisms of genetic heart diseases, utilising both human pluripotent stem cells as a human model of disease. At seven years post PhD, his research has attracted over $3 million in competitive funding and has been featured in leading journals such as Nature Cardiovascular Research, Science Translational Medicine, and Cell Metabolism. Recently, he has focused on the molecular function of the atypical kinase, ALPK3, in cardiac health and disease, which forms the basis of this award.
In 2020 he joined Professor Enzo Porrello and Associate Professor David Elliott’s groups at MCRI. Here, has risen to Team Leader, where he continues to study molecular mechanisms of genetic heart diseases, utilising both human pluripotent stem cells as a human model of disease. At seven years post PhD, his research has attracted over $3 million in competitive funding and has been featured in leading journals such as Nature Cardiovascular Research, Science Translational Medicine, and Cell Metabolism. Recently, he has focused on the molecular function of the atypical kinase, ALPK3, in cardiac health and disease, which forms the basis of this award.
Top Publications
- Blazev, R, Zee, BM, Peckham, H, Ng, Y-K, Lewis, CTA, Zhang, C, McNamara, JW, Goodman, CA, Gregorevic, P, Ochala, J, et al. Site-specific quantification of the in vivo UFMylome reveals myosin modification in ALS. 2026 view publication
- Hespe, S, Singer, ES, Reuter, C, Murray, B, Jordan, E, Chowns, J, Peters, S, Mayers, M, Gray, B, Hershberger, RE, et al. Clinical Validity of Autosomal Dominant ALPK3 Loss-of-function Variants as a Cause of Hypertrophic Cardiomyopathy. 2026 view publication
- McNamara, JW, Keen, EB, Sutton, R, She, Y, Mehdiabadi, NR, Griffen, B, Mills, RM, Hudson, JE, Titmarsh, DM, Porrello, ER, et al. Alpha Protein Kinase 3 Gene Therapy Restores Heart Function in Mouse and Human Models of Cardiomyopathy. 2026 view publication
- Chang, Y, Rath, EM, Soka, M, Singer, ES, Trivedi, G, Burns, C, Austin, R, Boughtwood, T, Brown, JS, Casauria, S, et al. Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses.. Genet Med 28(1) : 101626 2026 view publication
- Rzewnicki, S, Song, T, Singh, R, Ason, B, Maguire, M, Nieman, M, Lorenz, J, Gong, H, Kirk, J, Rapushi, E, et al. Abstract Wed126: Myosin S2 and cMyBP-C Interactions in Cardiac Contractility and Hypertrophic Cardiomyopathy. Circulation Research 137(Suppl_1) : 2025 view publication
Page 1 of 12
Career information
Share //
